PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Prescription medication · GLP-1 Receptor Agonist

dulaglutide

Also sold as Trulicity. Trulicity helps adults and children 10 years and older manage their type 2 diabetes.

Data updated 2026-05-15

85,635
FDA reportsOften reported
1
InteractionFew interactions
$471.69
Brand price (NADAC)

What the data shows

dulaglutide (Trulicity) is a prescription GLP-1 Receptor Agonist, more reported than most tracked drugs (85,635 FDA reports), with 1 documented drug interaction.

Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.

dulaglutide (Trulicity) is a prescription GLP-1 Receptor Agonist. Trulicity helps adults and children 10 years and older manage their type 2 diabetes.

Trulicity is a medicine to help control blood sugar in people with type 2 diabetes. It can also lower the risk of heart problems in adults with both type 2 diabetes and heart disease or heart risk factors.

Drug Pricing (NADAC)

Brand Price

$471.69/unit

Generic Available

No

Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →

View Alternatives → Compare with Another Drug → Full Side Effects Report →

What it does

Trulicity helps adults and children 10 years and older manage their type 2 diabetes.

Common side effects

Nausea, Diarrhea, Vomiting

Key warnings

Trulicity may cause thyroid tumors, including a type of thyroid cancer called medullary thyroid carcinoma (MTC).

The sections below are summarized in plain English from dulaglutide's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.

How It Works

Trulicity is a GLP-1 receptor agonist. It mimics a natural hormone in your body. This helps your body release insulin when your blood sugar is high and lowers the amount of sugar your liver makes.

How to Take It

You will inject Trulicity under your skin once a week. You can inject it any time of day, with or without food. Inject it in your stomach area, thigh, or upper arm. Be sure to change your injection site each week.

This is a plain-language summary of dulaglutide's FDA labeling, not individualized dosing advice. Ask a pharmacist or prescriber before changing how you take this medication.

Pregnancy & Breastfeeding

There is not enough information about Trulicity in pregnant women to know if it will harm an unborn baby. Trulicity should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Talk to your doctor if you are pregnant or plan to become pregnant.

This is a plain-language summary of dulaglutide's FDA labeling, not individualized advice. Ask a pharmacist or prescriber about pregnancy or breastfeeding on this medication.

Missed Dose

If you miss a dose, take it as soon as you remember if there are at least 3 days (72 hours) until your next scheduled dose. If less than 3 days remain, skip the missed dose and take your next dose on your regularly scheduled day.

This is a plain-language summary of dulaglutide's FDA labeling, not individualized advice. Ask a pharmacist or prescriber what to do about your specific missed dose.

Storage

Store Trulicity in the refrigerator between 36°F to 46°F (2°C to 8°C).

Side Effects (from patient reports)

Based on 85,635 FDA adverse event reports.

Most-reported reactions

Adverse reactions in FAERS for dulaglutide, by number of reports

reports

What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.

Source FDA Adverse Event Reporting System (FAERS) As of 2025

Reports over time

Adverse-event reports filed for dulaglutide each year to the FDA Adverse Event Reporting System (FAERS).

-5,00005,00010,00015,000 20112014201620182020202220242025 5,828

Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.

Where dulaglutide sits

dulaglutide has more FDA adverse-event reports than 83% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.

fewest reports most reports

Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is dulaglutide; the line is the median (50th percentile).

FDA Adverse Event Report Analysis

Detailed analysis of 85,635 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2011–2025.

Total Reports

85,635

Reports Mentioning Death

1,580

1.8% of reports — not proof of cause

Hospitalization Reports

10,007

Top Indication

Product Used For Unknown Indication

Gender Distribution

Female 44,406 (58%)
Male 32,394 (42%)

Age Distribution

0–17 127
18–44 3,325
45–64 17,698
65–74 11,124
75+ 5,637

Most Reported Adverse Reactions (FAERS)

# Reaction Reports
1 NAUSEA 9,986
2 INJECTION SITE PAIN 9,796
3 BLOOD GLUCOSE INCREASED 9,762
4 DIARRHOEA 5,737
5 INCORRECT DOSE ADMINISTERED 5,444
6 VOMITING 5,413
7 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 3,806
9 WEIGHT DECREASED 3,349
10 DECREASED APPETITE 3,153
11 INJECTION SITE HAEMORRHAGE 3,132
12 EXTRA DOSE ADMINISTERED 3,106
13 GLYCOSYLATED HAEMOGLOBIN INCREASED 2,906
14 FATIGUE 2,409
15 ACCIDENTAL UNDERDOSE 2,354
16 ABDOMINAL PAIN UPPER 2,321

Reactions in Death Reports

DEATH 722
PANCREATIC CARCINOMA 58
LACTIC ACIDOSIS 55
MYOCARDIAL INFARCTION 55
COVID-19 51
NAUSEA 47
PNEUMONIA 46
CARDIAC ARREST 42
VOMITING 42
DECREASED APPETITE 39

Reactions in Hospitalization Reports

NAUSEA 1,419
VOMITING 1,402
DIARRHOEA 1,078
IMPAIRED GASTRIC EMPTYING 743
BLOOD GLUCOSE INCREASED 717
ABDOMINAL PAIN 676
DEHYDRATION 668
PANCREATITIS 585
CONSTIPATION 509
DECREASED APPETITE 502

Source: FDA FAERS (Adverse Event Reporting System) FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation

Serious Warnings

Trulicity may cause thyroid tumors, including a type of thyroid cancer called medullary thyroid carcinoma (MTC). You should not use Trulicity if you or your family have ever had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your doctor if you have a lump in your neck, trouble swallowing, trouble breathing, or a hoarse voice that doesn't go away.

Known Drug Interactions

Monitor drug levels of oral medications with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with TRULICITY.

Mechanism: Dulaglutide can affect how your body absorbs other pills, which can be risky for drugs like warfarin that need to stay at a very specific level to work safely.

What to do: Your doctor should monitor your blood work closely to ensure your warfarin dose stays in the safe range.

This is a plain-language summary of interactions documented in FDA labeling, not individualized advice. Ask a pharmacist or prescriber before combining medications.

Common Questions

What should I do if I experience severe stomach pain?
Stop using Trulicity and contact your doctor right away, as this could be a sign of pancreatitis.
Can Trulicity cause low blood sugar?
Yes, especially if you are also taking insulin or a sulfonylurea medicine. Talk to your doctor about adjusting the dose of these other medicines.
What are the symptoms of a serious allergic reaction?
Symptoms can include swelling of your face, lips, tongue, or throat; trouble breathing or swallowing; severe rash or itching; fainting or feeling dizzy.
Can Trulicity affect my kidneys?
It might, especially if you have kidney problems or experience severe stomach issues. Your doctor may want to monitor your kidney function.
What if I have severe stomach problems?
Trulicity is not recommended if you have severe stomach problems, including gastroparesis.
Can Trulicity affect my eyes if I have diabetic retinopathy?
Yes, it can worsen diabetic retinopathy. Tell your doctor if you have a history of diabetic retinopathy so they can monitor you.
What if I think I have gallbladder problems?
Tell your doctor if you have symptoms like pain in your upper right abdomen, fever, nausea, or vomiting, as these could be signs of gallbladder problems.
Does Trulicity interact with other medications?
Yes, Trulicity can slow down the absorption of other oral medications you take. Your doctor may need to monitor the levels of certain medications, like warfarin.
How will I know if Trulicity is working?
Your doctor will check your blood sugar levels and A1C to see how well Trulicity is controlling your diabetes.
What if the Trulicity solution looks cloudy or has particles in it?
Do not use it. The solution should be clear and colorless. Contact your pharmacist for a new pen.
What are the common side effects of dulaglutide?
The most commonly reported side effects of dulaglutide include Nausea, Diarrhea, Vomiting, Abdominal pain, Decreased appetite. Based on 85,635 FDA adverse event reports. Always consult your healthcare provider about potential side effects.
Does dulaglutide interact with other medications?
Yes, dulaglutide has 1 known drug interactions. Notable interactions include warfarin. Always inform your doctor about all medications you are taking.
What drug class is dulaglutide?
dulaglutide belongs to the GLP-1 Receptor Agonist drug class. It requires a prescription (Rx). Trulicity helps adults and children 10 years and older manage their type 2 diabetes.
Is dulaglutide safe during pregnancy?
There is not enough information about Trulicity in pregnant women to know if it will harm an unborn baby. Trulicity should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Always consult your healthcare provider before using any medication during pregnancy or breastfeeding.

Related Medications in GLP-1 Receptor Agonist

Other drugs grouped near dulaglutide - same-class peers and common alternatives.

Compare dulaglutide vs acarbose side-by-side →

Medication Guides

Save on dulaglutide

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for dulaglutide

The FDA label for dulaglutide (sold under brand names such as Trulicity) classifies it as a prescription-only medication in the GLP-1 Receptor Agonist class. Trulicity helps adults and children 10 years and older manage their type 2 diabetes. Official labeling lists 5 commonly reported side effects, including Nausea, Diarrhea, Vomiting.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 85,635 voluntary reports. The database also lists 1 documented drug interaction derived from FDA labeling, with the top-flagged interaction rated minor severity. NADAC pricing from CMS.

Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice, always consult a licensed healthcare provider before starting, stopping, or changing any medication.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.

Last updated: August 5, 2023

Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled and last refreshed May 2026. See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

All federal data sources used on this page